INS and metabolic dysfunction-associated steatotic liver disease: In addition to the direct adverse effects these therapies have on the liver, the treatments likely lead to an enhanced risk of NAFLD through an increase in body weight and/or reduction in lean mass, with lipid and glucose-insulin alterations [63].